Clinical Efficacy and Safety of High-Dose Dexamethasone Plus Low-Dose Rituximab as First-Line Therapy in Newly Diagnosed Primary Immune Thrombocytopenia
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Efficacy and Safety of High-Dose Dexamethasone Plus Low-Dose Rituximab as First-Line Therapy in Newly Diagnosed Primary Immune Thrombocytopenia
Authors
Keywords
Immune thrombocytopenia, Newly diagnosed, Rituximab, Dexamethasone
Journal
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2019-01-01
DOI
10.1007/s12288-018-1061-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Low Dose Rituximab in Chronic ITP: Still an Option in Resource Limited Settings
- (2016) Rajan Kapoor et al. INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION
- Low Dose Rituximab in Chronic ITP: Still an Option in Resource Limited Settings
- (2016) Rajan Kapoor et al. Indian Journal of Hematology and Blood Transfusion
- Current Management of Primary Immune Thrombocytopenia
- (2015) Drew Provan et al. ADVANCES IN THERAPY
- Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial
- (2015) Waleed Ghanima et al. LANCET
- Rituximab for adult primary immune thrombocytopenia
- (2015) Henrik Frederiksen Lancet Haematology
- Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis
- (2015) Shaan Chugh et al. Lancet Haematology
- Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients
- (2014) M. Khellaf et al. BLOOD
- Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia
- (2013) S. Gudbrandsdottir et al. BLOOD
- Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group
- (2013) F. Rodeghiero et al. BLOOD
- High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia
- (2013) David Gómez-Almaguer et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia
- (2012) Francesco Zaja et al. AMERICAN JOURNAL OF HEMATOLOGY
- The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
- (2011) C. Neunert et al. BLOOD
- Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia
- (2010) F. Zaja et al. BLOOD
- Low-dose rituximab in adult patients with primary immune thrombocytopenia
- (2010) Francesco Zaja et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- The Long-term Impact of Rituximab for Childhood Immune Thrombocytopenia
- (2010) Nichola Cooper et al. Current Rheumatology Reports
- International consensus report on the investigation and management of primary immune thrombocytopenia
- (2009) D. Provan et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now